

Article

Combining awake anesthesia with minimal invasive surgery optimizes intraoperative surgical spinal cord stimulation lead placement

Philippe Rigoard ^{1,2,3}, Amine Ounajim ¹, Lisa Goudman ^{4,5,6}, Chantal Wood ¹, Manuel Roulaud ¹, Philippe Page ², Bertille Lorgeoux ¹, Sandrine Baron ¹, Kevin Nivole ¹, Mathilde Many ¹, Emmanuel Cuny ⁷, Jimmy Voirin ⁸, Denys Fontaine ^{9,10}, Sylvie Raoul ¹¹, Patrick Mertens ¹², Philippe Peruzzi ¹³, François Caire ¹⁴, Nadia Buisset ¹⁵, Romain David ^{1,16}, Maarten Moens ^{4,5,17,†}, and Maxime Billot ^{1, †, *}

¹ PRISMATICS Lab (Predictive Research in Spine/Neuromodulation Management and Thoracic Innovation/Cardiac Surgery), Poitiers University Hospital, 86021 Poitiers, France;

² Department of Neuro-Spine & Neuromodulation, Poitiers University Hospital, 86000 Poitiers, France;

³ Pprime Institute UPR 3346, CNRS, ISAE-ENSMA, University of Poitiers, 86000 Poitiers, France;

⁴ Department of Neurosurgery, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium;

⁵ STIMULUS consortium (reSearch and TeachIng neuroModULation Uz bruSsel), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium;

⁶ Research Foundation—Flanders (FWO), 1090 Brussels, Belgium;

⁷ Department of Neurosurgery, Bordeaux University Hospital, Bordeaux, France;

⁸ Department of Neurosurgery, Colmar Hospital, Colmar, France;

⁹ Centre Hospitalier Universitaire de Nice, Department of Neurosurgery, Université Côte d'Azur, Nice, France;

¹⁰ FHU InovPain, Côte Azur University, Nice, France;

¹¹ Department of Neurosurgery, Nantes University Hospital, Nantes, France;

¹² Department of Neurosurgery, Lyon University Hospital, Lyon, France;

¹³ Department of Neurosurgery, Reims University Hospital, Reims, France;

¹⁴ Department of Neurosurgery, Limoges University Hospital, Limoges, France;

¹⁵ Department of Neurosurgery, Lille University Hospital, Lille, France;

¹⁶ Physical and Rehabilitation Medicine Unit, Poitiers University Hospital, University of Poitiers, 86021 Poitiers, France.

¹⁷ Department of Radiology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

* Correspondence: maxime.billot@chu-poitiers.fr

† Shared co-last authorship

Abstract: Spinal Cord Stimulation (SCS) is an effective and validated treatment to address chronic refractory neuropathic pain in Persistent Spinal Pain Syndrome-Type 2 (PSPS-T2) patients. Surgical SCS lead placement is traditionally performed under general anesthesia due to its invasiveness. In parallel, recent works have suggested that Awake Anesthesia (AA), consisting in Target Controlled Intra-Veinous Anesthesia (TCIVA), could be an interesting tool to optimize lead anatomical placement using patient intra-operative feedback. We hypothesized that combining AA with Minimal Invasive Surgery (MIS) could improve SCS outcomes. The goal of this study was to evaluate SCS lead performance (defined by the area of pain adequately covered by paraesthesia generated via SCS), using an intraoperative objective quantitative mapping tool, and secondarily to assess pain relief, functional improvement and change in quality of life with a composite score. We analyzed data from a prospective multicenter study (ESTIMET) to compare the outcomes of 115 patients implanted with MIS under AA (MISAA group) or General Anesthesia (MISGA group), or by Laminectomy under General Anesthesia (LGA group). All in all, MISAA appears to show significantly better performance in terms of patient pain coverage, as well as improved secondary outcomes. One step further, our results suggest that MISAA combined with intra-operative hypnosis could potentialize patient intraoperative cooperation and could be proposed as a personalized package offered to PSPS-T2 patients eligible for SCS implantation in highly dedicated neuromodulation centers.

Keywords: PSPS; FBSS; SCS; surgical lead; SCS implantation; MAST (for Minimal Access Spine Technologies); TCIVA (for Target Controlled Intra-Veinous Anesthesia); composite score; pain mapping; neuropathic pain; chronic pain; quality of life; anesthesia; hypnosis.

1. Introduction

Spinal cord stimulation (SCS) is considered as a useful tool to manage chronic refractory pain [1–6], including persistent spinal pain syndrome after surgery (PSPS-T2) [7], when the neuropathic component is significant [8–12]. During the last decades, technological refinements have shown promising perspectives in two directions:

- SCS temporal resolution has been the subject of intensive research, making new waveforms available for the last generation of internal pulse generators (IPG). This modulates temporal resolution of the electrical signal in view of obtaining better pain relief, less discomfort and more personalized therapy by selecting or even combining several signals at the same time [13–18]. This also identifies new SCS mechanisms of action conveyed by different patterns from the classical gate control theory [19–22].
- SCS spatial resolution has been optimized through multiplication of contacts at the surface of implanted leads, generating more precise and complex electrical fields, in view of enhancing spatial neural targeting [16,23].

Wishing to obtain optimal paresthesia coverage using conventional tonic SCS in order to achieve better pain relief, we have started to implant surgical leads under Awake Anesthesia (AA) so as to optimize spatial neural targeting with or without hypnosis [8,24] in a dedicated operating theatre [25,26]. We initially developed this approach using multicolumn surgical lead implantation for back and leg pain indications in PSPS-Type 2 patients. To minimize surgical trauma, we developed a new surgical approach requiring Minimal Invasive Surgery (MIS), based on Minimal Access Spinal Technologies (MAST) [27,28]. MAST allowed us to perform SCS surgical implantation under Target Controlled Intra-Venous Anesthesia (TCIVA), making it possible to assess the patient intraoperatively with high-fidelity despite surgical lead invasiveness. Intra-operative testing using quantitative measurements of pain surface, pain intensity, pain typology, and paresthesia coverage was implemented through an interactive tactile interface specifically developed for this purpose [16,29–32]. The mapping tool and software (Neuro-Mapping Locator™ / NML) provide novel indices to instantaneously assess / compare lead performance (percentage of pain area covered by paresthesia generated via SCS) and lead selectivity (percentage of paresthesia adequately overlapping painful territories) defining an “R index”, with intraoperative objective data. We hypothesized that combining AA with MIS could improve SCS outcomes.

We designed a national prospective multicenter study to evaluate the ability of multicolumn SCS to optimize back pain coverage and pain relief using complex multicolumn programming [3], and to compare lead placement optimization in PSPS-T2 patients implanted with surgical leads using a broad spectrum of surgical approaches. This study was performed in 12 French expert centers. In the vast majority of centers, patients were implanted using minimal invasive surgery under General Anesthesia (MISGA). In some centers, patients were implanted using traditional laminectomy under general anesthesia (LGA). All patients operated in the center X, were implanted using a combination of MIS with AA (MISAA), consisting in TCIVA + intraoperative hypnosis [24], allowing for intraoperative mapping assessment with NML™ software.

In the present study, our specific goal was to evaluate whether all the above-mentioned conditions deployed to optimize intraoperative patient feedback would contribute to optimize lead placement and thereby obtain significantly better pain coverage and/or clinical outcomes.

2. Materials and Methods

2.1. Objectives

Our primary objective was to analyze the impact of lead placement approach on SCS performance (paresthesia coverage) in paresthesia-based stimulation mode. To achieve this, we compared lead performance and lead selectivity of multicolumn SCS between the three groups of implanted patients: MISAA group, MISGA group and LGA group. Our secondary objectives were to compare pain relief (global, back and leg), functional improvement, psychological distress, improvement in quality of life and global health after 12 months of follow-up.

2.2. Study design

Data were collected during the ESTIMET study, which was a multicenter prospective randomized controlled trial, including 115 PSPS-T2 patients eligible for SCS and implanted with surgical multicolumn SCS lead, in 12 French centers with a 1-year follow-up [3,33]. The primary objective of this study was to compare 6-month outcomes between multicolumn programming SCS and monocolumn programming SCS. 104 patients were permanently implanted after a successful multicolumn 5-6-5 lead trial. As part of the ESTIMET study, data collection was conducted according to the guidelines of the Declaration of Helsinki & the French Data Protection Authority (CNIL, MR-001), and approved by the Ethics Committee "CPP Ouest III" and the French Agency for the Safety of Health Products "ANSM" (number: 2011-A01695-36). The ClinicalTrials.gov Identifier is: NCT01628237. All subjects involved in the study provided written informed consent.

2.3. Study population

The study population consisted of PSPS-T2 patients, defined as patients suffering from persistent back and leg pain for at least six months following at least one surgical procedure, with pain refractory to well-conducted conservative management under the guidance of a multidisciplinary pain clinic. Standard clinical practice at each site according to the French guidelines of the National Health Authority (HAS) for SCS selection and implantation facilitated SCS eligibility identification. Systematic evaluation of patients for ESTIMET study eligibility according to several inclusion criteria led to enrollment, before which patients provided consent.

Study patients had a PSPS-T2 diagnosis with chronic back and leg pain characterized by neuropathic component (DN4 questionnaire, sensorimotor testing, clinical examination, pain characteristics, etc.); significant unilateral or bilateral radicular pain with mean intensity on a Visual Analogue Scale (VAS) ≥ 50 mm (collected daily over five consecutive days) associated with a significant back pain component; and no further spine surgery indication.

Exclusion criteria included previous SCS treatment; subcutaneous or peripheral nerve stimulation; an intrathecal drug delivery system; experimental treatments; back surgery at the site related to the patient's original back complaint requirement; and/or presenting a surgical, anesthetic, or psychiatric contraindication to SCS treatment.

Patients who did not meet all of the inclusion criteria or who met at least one of the exclusion criteria were discontinued from the study.

2.4. Procedures

All patients were implanted with a multicolumn SCS surgical lead (Specify 5-6-5, Medtronic, Minneapolis, MN). All neurosurgeons were considered experts in surgical SCS implantation. Additional implantation guidelines and two cadaver courses were used to homogenize implanting practices. All patients were implanted in the prone position. The lead tip was positioned between T7 and T10 based on the level of the conus medullaris assessed by preoperative spinal magnetic resonance imaging. A radiographic assessment of lead position was conducted prior to wound closure in order

to ensure anatomic midline placement, thoracic implantation level and lack of lead twisting. Finally, an impedance check ensured system integrity.

In all 11 centers other than center X, patients were implanted under conventional general anesthesia. Leads were implanted over the spinal cord segments receiving the dorsal root fibers corresponding to the painful segment of the back.

In center X, patients were implanted under awake surgery by Target-Controlled IntraVenous Anesthesia (TCIVA), which enabled lead placement on the physiologic midline by intraoperative testing according to patient-reported optimal paresthesia coverage. Patients also had the option of receiving intraoperative hypnosis by a qualified hypnotherapist and/or a VR device (Figure 1) [24]. During the lead implantation surgery, patients also had access to a pain mapping tool (Figure 1 & 2), through which patients could not only draw their pain surface on a body map, but also draw the paresthesia coverage following stimulation [34]. This allowed the implanter of patients under awake anesthesia to adjust the lead position intraoperatively until achieving optimal performance and selectivity.

Data were collected from patients at baseline, and at 1-, 3-, 6- and 12-month follow-up visits.




Figure 1. Surgical lead implantation (A&B) under awake surgery with intraoperative hypnosis (C) which enabled lead placement on the physiologic midline by intraoperative testing according to patient-reported optimal paresthesia coverage (D). Pain mapping software used to assess pain surface before implantation (D1) and pain coverage where the patient could draw different painful zones intraoperatively (D2).

2.5. Subgroup analysis

Patients were allocated retrospectively to one of the three following sub-groups:

- 1) The first sub-group includes patients having undergone optimized lead positioning through minimal invasive surgery under awake anesthesia (MISAA group) using TCIVA.

- 2) The second group includes patients having undergone lead placement through minimal invasive surgery under general anesthesia (MISGA group).
- 3) The third sub-group includes patients having undergone anatomic lead placement with laminectomy under general anesthesia (LGA group).

2.6. Study outcomes

The pain mapping outcomes were considered as primary outcomes with the two following components:

- Paresthesia coverage was evaluated as the percentage of pain covered by paresthesia. This percentage is calculated as the surface of pain (in cm²) covered by paresthesia divided by the total pain surface.
- Selectivity was evaluated as the percentage of paresthesia covering pain (i.e. the surface of pain covered by paresthesia divided by the total paresthesia surface).

The following clinical outcomes were considered as secondary outcomes between baseline, 6- and 12-month follow-up visits:

- Global pain relief was evaluated by the percentage of global pain decrease and the percentage of patients with a 50% pain decrease.
- Back pain relief was evaluated by the percentage of back pain decrease.
- Leg pain relief was evaluated by the percentage of leg pain decrease.
- Functional improvement was evaluated by the percentage of decrease of the Oswestry Disability Questionnaire (ODI).
- Quality of life improvement was assessed using the absolute increase in EuroQoL-5 Dimensions 3 Level (EQ-5D-3L) index.
- Depression level was evaluated using the Montgomery-Asberg Depression Scale.
- Holistic composite evaluation was used to provide a score representing the patient's Global Health Score (GHS). This score includes pain intensity (VAS), functional disability (ODI), quality of life (EQ5D), depression (MADRS) and pain surface. The score was calculated based on a Principal Component Analysis (PCA) including these 5 variables [31,35]. The first principal component served as the global multidimensional score. The score was then scaled to 0 (worst global health) to 10 (best global health) for easier interpretations. The absolute difference between baseline and each follow-up was used to evaluate overall health improvement.
- Complication rates following the lead implantation were also reported and compared between the three groups.

2.7. Statistical analysis

The statistical analyses were conducted using R software (Version 3.6.0, R Foundation for Statistical Computing, Vienna, Austria).

Baseline characteristics were described for each group using means (standard deviation) for quantitative variables or number (percentage) for qualitative variables. In order to verify the comparability of the three groups, their baseline characteristics were compared using a one-factor ANOVA test for continuous variables (or a Kruskal-Wallis test in case of non-normality) and a Chi-squared test (Fisher's exact test in case of small numbers) for qualitative variables. Normality was verified using a Shapiro-Wilk test.

Continuous outcomes were compared between the three groups using either a one-factor ANOVA or a Kruskal-Wallis test depending on the normality of the outcome. Qualitative outcomes were compared using either a Chi-squared test or Fisher's exact test.

In case baseline characteristics showed a significant difference between the three groups, these characteristics were then included in a multiple regression model as confounding variables when comparing the outcomes between the three groups.

When the one-factor ANOVA of an outcome showed a significant difference between the three groups, then multiple pairwise comparisons were conducted between each two groups to identify which groups were significantly different from the others. Since we conducted multiple comparisons, a Bonferroni correction was applied on the p-values to adjust for the false discovery rate.

P-values lower than 0.05 were considered significant and all tests were two-tailed. No missing value imputation was conducted and data were analyzed based on an available-case principle.

3. Results

3.1. Patients characteristics

A total of 115 PSPS-T2 patients were included in the study. Two patients were excluded due to psychiatric disorders and 4 patients for meeting an exclusion criterion. Among the remaining 109 patients, 1 patient withdrew his consent before lead implantation. A total of 108 patients underwent a multicolumn lead trial; 23 patients were implanted with lead using the minimal invasive surgery awake anesthesia (MISAA group), while 52 patients were implanted by minimal invasive surgery under general anesthesia (MISGA group), and the remaining 33 patients were implanted by laminectomy under general anesthesia (LGA group). The final analyzed sample consisted in 22 patients in the MISAA group, 48 patients in the MISGA group and 27 patients in the LGA group (Figure 2).




Figure 2. Study flow chart.

Baseline characteristics of the study groups are presented in Table 1. The mean age of the three groups was 46.4 ± 7.6 years for the MISAA group, 50.7 ± 9.5 years for the LGA group and 46.2 ± 9.4 years for the MISGA group, without any significant difference between groups ($p=0.21$). Gender distribution was not significantly different between groups ($p=0.62$) with 39.1%, 50% and 51.5% of males in the MISAA, MISGA and LGA groups, respectively. The MADRS score was significantly higher for the MISAA (20.0 ± 9.8) and LGA (21.3 ± 11.8) than the MISGA (14.1 ± 9.7) group ($p = 0.005$). The number of previous spinal surgeries was significantly higher for the LGA and MISGA (median:2, range 1-5) groups in comparison with the MISAA group (median: 1, range: 1-3) ($p = 0.026$). The MADRS and number of previous spinal surgeries were therefore included in a regression model as confounding variables in order to compare the study outcomes between the three groups. The other baseline characteristics were not significantly different between groups (please see Table 1 for details).

Table 1. Baseline characteristic comparisons between the MISAA, MISGA and LGA groups.

	MISAA group n = 23	MISGA group n = 52	LGA group n = 33	p-value of the difference
Age (years)	46.4 ± 7.6	46.2 ± 9.4	50.7 ± 9.5	0.21
Sex male/female n (%)	9/14 (39.1%)	26/26 (50%)	17/16 (51.5%)	0.62
BMI (kg/m ²)	26.7 ± 4.3	26.8 ± 4.7	28.0 ± 6.3	0.72
Pain duration (years)	11.7 ± 9.2	11.3 ± 9.7	12.8 ± 12.5	0.8
Global VAS (mm)	71.5 ± 13.3	76.0 ± 11.5	75.7 ± 14.2	0.33
Back pain VAS (mm)	71.1 ± 18.1	74.1 ± 16.9	75.9 ± 14.8	0.62
Leg pain VAS (mm)	75.7 ± 9.0	78.7 ± 11.1	73.9 ± 15.1	0.20
Pain surface in cm ² (median (IQR))	522.7 (921.6)	807 (969.5)	503.4 (924.6)	0.12
Patients with predominant back pain back/leg n (%)	9/14 (39.1%)	15/37 (28.8%)	15/18 (45.5%)	0.28
Patients with a neuropathic component (%)				
Back pain n (%)	13/10 (56.5%)	29/23 (55.8%)	18/15 (56.3%)	0.99
Leg pain n (%)	22/1 (95.7%)	52/0 (100%)	33/0 (100%)	0.21
Number of previous spinal surgeries (median (min-max))	1 (1-3)	2 (1-5)	2 (1-5)	0.026
MADRS depression score	20.0 ± 9.8	14.1 ± 9.7	21.3 ± 11.8	0.005
BAS anxiety score	19.5 ± 8.2	17.7 ± 8.1	18.3 ± 6.5	0.57

BAS: Brief anxiety scale; IQR: Interquartile range; MADRS: Montgomery-Asberg Depression Rating Scale; MISAA: Minimal Invasive Surgery under Awake Anesthesia; MISGA: Minimal Invasive Surgery under General Anesthesia; LGA: Laminectomy under General Anesthesia; VAS: Visual Analogic Scale.

Lead implantation parameters and IPG characteristics are presented in Table 2. We found a significant difference in lead lateralization ($p = 0.003$) and in permanent IPG type (i.e. rechargeable/non-rechargeable) ($p = 0.0006$) between groups.

Regarding lead lateralization for the MISAA group, 30.5% of the leads had a lateralization on the right in the upper part and on the midline in the lower part. For the LGA and MISGA groups the majority of leads were implanted at the midline in both the upper and the lower parts (60.6% of the leads for the LGA group and 55.8% for the MISGA group). Regarding the type of IPG, the majority (69.6%) of IPGs were non-rechargeable for the MISAA group. Similarly, the majority (78.8%) of IPGs were non-rechargeable for the LGA group. For the MISGA group, on the other hand, the majority (53.8%) of IPGs were rechargeable.

The remaining device-related parameters were similar between the three groups ($p > 0.05$).

Table 2. Lead implantation parameters and IPG characteristics for each group.

	MISAA group n = 23	MISGA group n = 52	LGA group n = 33	p-value of the difference
Vertebral level projection of the conus medullaris				0.12
T11-T12	0 (0%)	5 (9.6%)	0 (0%)	
T12-L1	15 (65.2%)	28 (53.8%)	25 (75.8%)	
L1-L2	8 (34.8%)	16 (30.8%)	7 (21.2%)	
L2-L3	0 (0%)	0 (0%)	1 (3.0%)	
Unknown	0 (0%)	3 (5.8%)	0 (0%)	
Lead lateralization (Up- per/lower) (n, %)				0.003
Right/Right	2 (8.7%)	9 (17.3%)	1 (3.0%)	
Right/Left	0 (0%)	0 (0%)	1 (3.0%)	
Right/Midline	7 (30.5%)	3 (5.8%)	6 (18.2%)	
Left/Right	0 (0%)	0 (0%)	0 (0%)	
Left/Left	0 (0%)	5 (9.6%)	1 (3.0%)	
Left/Midline	5 (21.7%)	3 (5.8%)	1 (3.0%)	
Midline/Right	1 (4.3%)	0 (0%)	1 (3.0%)	
Midline/Left	3 (13.0%)	3 (5.8%)	0 (0%)	
Midline/Midline	5 (21.7%)	29 (55.8%)	20 (60.6%)	
Unknown	0 (0%)	0 (0%)	2 (6.1%)	
Vertebral level projection of the central contact “number 8” of the 5-6-5 lead.				0.32
T11	1 (4.3%)	1 (1.9%)	0 (0%)	
T10	2 (8.7%)	8 (15.4%)	5 (15.2%)	
T9	16 (69.6%)	22 (42.3%)	14 (42.4%)	
T8	4 (17.4%)	15 (28.8%)	9 (27.3%)	
T7	0 (0%)	6 (11.5%)	1 (3%)	
T6	0 (0%)	0 (0%)	1 (3%)	
Unknown	0 (0%)	0 (0%)	3 (9.1%)	
IPG type				0.0006
Non rechargeable	16 (69.6%)	23 (44.2%)	26 (78.8%)	
Rechargeable	7 (30.4%)	28 (53.8%)	4 (12.1%)	
Not implanted per- manently	0 (0%)	1 (1.9%)	3 (9.1%)	

IPG: Internal Pulse Generator; MISAA: Minimal Invasive Surgery under Awake Anesthesia; MISGA: Minimal Invasive Surgery under General Anesthesia; LGA: Laminectomy under General Anesthesia.

3.2. Comparison of pain mapping outcomes between the groups

The comparisons of paresthesia coverage, selectivity, and pain surface at each follow-up visit are presented in Table 3.

Paresthesia coverage (% of pain covered by paresthesia) was significantly different between groups at 1- ($p = 0.01$), 3- ($p = 0.014$), 6- ($p = 0.003$), and 12-month follow-up periods ($p = 0.03$) (Figure 3). More specifically, at 1- and 3-month follow-up, the paresthesia coverage was greater in the MISAA group ($66.0 \pm 34.6\%$; $65.1 \pm 33.7\%$) compared to the MISGA ($41.6 \pm 34.0\%$, $p = 0.009$; $43.8 \pm 31.8\%$, $p = 0.017$) and LGA groups ($37.8 \pm 33.0\%$, $p = 0.007$; $36.5 \pm 36.0\%$, $p = 0.0096$). In addition, paresthesia coverage was greater for the MISAA in comparison with LGA at 6- ($65.3 \pm 38.2\%$ vs $33.8 \pm 31.9\%$, $p = 0.004$) and 12-month ($64.1 \pm 36.7\%$ vs $36.6 \pm 37.4\%$, $p = 0.015$) follow-up, and greater for the MISGA group compared to the LGA group at 6-month follow-up (MISGA: $56.5 \pm 32.1\%$ vs LGA: $33.8 \pm 31.9\%$, $p = 0.008$). No difference was found between paresthesia coverage of the MISAA and MISGA groups at 6- ($p = 0.15$) and 12-month ($p = 0.12$) follow-up, and between MISGA and LGA at 12-month follow-up ($p = 0.11$).

Table 3. Comparison of the pain mapping outcomes among the MISAA, MISGA, and LGA groups at 1-, 3-, 6- and 12-month follow-up.

Follow-up visits	MISAA group	MISGA group	LGA group	Adjusted p-value*
1-month	n = 22	n = 50	n = 28	
Paresthesia coverage (%)	$66.0\% \pm 34.6\%^a$	$41.6\% \pm 34.0\%^b$	$37.8\% \pm 33.0\%^b$	0.010
Selectivity (%)	$31.2\% \pm 28.0\%$	$53.6\% \pm 38.3\%$	$41.3\% \pm 37.8\%$	0.11
% of pain surface decrease	$76.2\% \pm 30.5\%^a$	$54.0\% \pm 38.1\%^b$	$56.3\% \pm 41.4\%^{a,b}$	0.038
3-month	n = 22	n = 50	n = 28	
Paresthesia coverage (%)	$65.1\% \pm 33.7\%^a$	$43.8\% \pm 31.8\%^b$	$36.5\% \pm 36.0\%^b$	0.014
Selectivity (%)	$30.8\% \pm 27.2\%^a$	$59.4\% \pm 33.4\%^b$	$42.4\% \pm 37.1\%^{a,b}$	0.011
% of pain surface decrease	$68.5\% \pm 38.6\%^a$	$44.0\% \pm 37.8\%^b$	$57.8\% \pm 34.6\%^{a,b}$	0.019
6-month	n = 22	n = 50	n = 28	
Paresthesia coverage (%)	$65.3\% \pm 38.2\%^a$	$56.5\% \pm 32.1\%^a$	$33.8\% \pm 31.9\%^b$	0.0033
Selectivity (%)	$26.5\% \pm 23.7\%^a$	$61.8\% \pm 33.6\%^b$	$37.2\% \pm 36.6\%^a$	0.0008
% of pain surface decrease	$50.5\% \pm 44.4\%$	$53.1\% \pm 41.7\%$	$50.3\% \pm 38.4\%$	0.9
12-month	n = 22	n = 48	n = 27	
Paresthesia coverage (%)	$64.1\% \pm 36.7\%^a$	$51.1\% \pm 34.5\%^{a,b}$	$36.6\% \pm 37.4\%^b$	0.032
Selectivity (%)	$27.5\% \pm 22.7\%^a$	$55.3\% \pm 36.0\%^b$	$30.1\% \pm 34.9\%^a$	0.011
% of pain surface decrease	$64.6\% \pm 40.3\%$	$61.3\% \pm 34.8\%$	$51.6\% \pm 42.4\%$	0.42

*p-values were adjusted for the differences among the groups and for multiple comparisons. Values with a different exponent were significantly different in the post-hoc pairwise analysis. MISAA: Minimal Invasive Surgery under Awake Anesthesia; MISGA: Minimal Invasive Surgery under General Anesthesia; LGA: Laminectomy under General Anesthesia. ^{a,b} Values with a different exponent were significantly different in the post-hoc pairwise analysis.




Figure 3. Mean paresthesia coverage (% of pain surface covered by paresthesia) for the MISAA (in blue), MISGA (in white), and LGA (in red) groups at 1, 3, 6 and 12-month follow-up visits. MISAA: Minimal Invasive Surgery under Awake Anesthesia; MISGA: Minimal Invasive Surgery under General Anesthesia; LGA: Laminectomy under General Anesthesia. * $p < 0.05$, ** $p < 0.01$, significant difference between groups.

Lead selectivity (% of paresthesia covering pain area adequately) was not significantly different between groups at 1-month follow-up ($p = 0.11$), whereas a significant main effect of group was observed at 3- ($p = 0.011$), 6- ($p = 0.0008$), and 12-month ($p = 0.011$) follow-up. More specifically, at 3, 6, and 12 months, selectivity was significantly higher for the MISGA group ($59.4 \pm 33.4\%$ at 3-month; $61.8 \pm 33.6\%$ at 6-month; $55.3 \pm 36.0\%$ at 12-month) compared to the MISAA group ($30.8 \pm 27.2\%$, $p = 0.0026$; $26.5 \pm 23.7\%$, $p = 0.002$; $27.5 \pm 22.7\%$, $p = 0.008$). In addition, selectivity was higher for the MISGA than LGA group at 6- ($61.8 \pm 33.6\%$ vs $37.2 \pm 36.6\%$, $p = 0.024$) and 12-month ($55.3 \pm 36.0\%$ vs $30.1 \pm 34.9\%$, $p = 0.024$) follow-up. No significant difference in selectivity was observed between MISGA and LGA at 3-month follow-up ($p = 0.11$), and between MISAA and LGA groups at 3- ($p = 0.44$), 6- ($p = 0.59$), and 12-month follow-up ($p = 0.64$).

The percentage of pain surface decrease was significantly different between groups at 1- ($p = 0.038$) and 3-month ($p = 0.019$) follow-up, but not at 6- ($p = 0.9$) and 12-month ($p = 0.42$) follow-up. More specifically, at 1 and 3 months, the percentage of pain surface decrease was higher for the MISAA ($76.2 \pm 30.5\%$; $68.5 \pm 38.6\%$) than for the MISGA group ($54.0 \pm 38.1\%$, $p = 0.012$; $44.0 \pm 37.8\%$, $p = 0.008$). No significant difference was found between the MISAA and LGA groups ($p > 0.147$), or between the MISGA and LGA groups ($p > 0.146$).

3.3. Comparison of clinical outcomes between groups after 6 and 12 months

Clinical outcomes between groups after 6 and 12 months are presented in Table 4.

3.3.1. Overall pain relief

Overall VAS relief was significantly different between groups at 6 months ($p = 0.047$), but not at 12 months ($p = 0.076$). At 6 months, overall pain VAS relief was higher for the MISAA group ($60.4\% \pm 31.9\%$) compared to the LGA group ($35.4\% \pm 39.4\%$, $p = 0.023$), without any significant difference with the MISGA group ($45.5\% \pm 32.8\%$, $p = 0.076$). No significant difference was found between the MISGA and the LGA groups ($p = 0.26$).

Table 4. Comparison of the clinical outcomes between the AG and TCI groups at 6 and 12-month follow-up.

Clinical outcomes at 6-month follow-up	MISAA group n = 22	MISGA group n = 50	LGA group n = 28	Adjusted p-value*
% of decrease in global VAS	60.4% ± 31.9% ^a	45.5% ± 32.8% ^{a,b}	35.4% ± 39.4% ^b	0.047
% of decrease in back VAS	52.6% ± 35.6% ^a	43.2% ± 34.1% ^a	18.9% ± 39.3% ^b	0.0037
% of decrease in leg VAS	79.0% ± 22.3% ^a	55.7% ± 34.3% ^b	54.2% ± 44.2% ^b	0.016
% of decrease in ODI	44.4% ± 32.5% ^a	26.8% ± 34.0% ^{a,b}	22.3% ± 25.4% ^b	0.028
Absolute increase in EQ-5D-3L	0.31 ± 0.19 ^a	0.14 ± 0.25 ^{a,b}	0.17 ± 0.26 ^b	0.039
Absolute decrease in MADRS	12.3 ± 12.0 ^a	1.8 ± 7.2 ^b	3.5 ± 10.2 ^a	0.0003
Clinical outcomes at 12-month follow-up	MISAA group n = 22	MISGA group n = 48	LGA group n = 27	Adjusted p-value*
% of decrease in global VAS	59.0% ± 31.7% ^a	44.0% ± 36.2% ^a	35.9% ± 38.1% ^a	0.076
% of decrease in back VAS	55.9% ± 38.0% ^a	42.7% ± 39.0% ^a	27.7% ± 44.0% ^a	0.080
% of decrease in leg VAS	73.5% ± 26.5% ^a	52.9% ± 31.7% ^b	46.4% ± 36.7% ^b	0.012
% of decrease in ODI	48.0% ± 28.3% ^a	27.5% ± 36.5% ^{a,b}	31.4% ± 28.8% ^b	0.033
Absolute increase in EQ-5D-3L	0.26 ± 0.16 ^a	0.12 ± 0.27 ^b	0.25 ± 0.22 ^a	0.015
Absolute decrease in MADRS	12.2 ± 9.4 ^a	2.9 ± 9.9 ^b	6.5 ± 10.5 ^a	0.0005

VAS: Visual Analogic Scale; ODI: Oswestry Disability Index; EQ-5D-3L: EuroQol-5 Dimensions. *p-values were adjusted for the differences between the groups in MADRS and number of surgeries and for multiple comparisons. ^{a,b} Values with a different exponent were significantly different in the post-hoc pairwise analysis.

3.3.2. Back pain relief

Back pain VAS relief was significantly different between groups at 6 months ($p = 0.0037$), but not at 12 months ($p = 0.08$). More specifically, at 6-month follow-up, back pain VAS relief was significantly lower for the LGA group ($18.9\% \pm 39.3\%$) compared to the MISAA ($52.6\% \pm 35.6\%$, $p = 0.0021$) and MISGA ($43.2\% \pm 34.1\%$, $p = 0.0036$) groups. No significant difference in back pain relief was observed between the MISAA and MISGA groups ($p = 0.32$) at 6 months.

3.3.3. Leg pain relief

Leg pain VAS relief was significantly different between groups at 6- ($p = 0.016$) and 12-month ($p = 0.012$) follow-up, with significant higher leg pain VAS relief in the MISAA group ($79.0\% \pm 22.3\%$ at 6-month; $73.5 \pm 26.5\%$ at 12-month) in comparison with the MISGA ($55.7\% \pm 34.3\%$, $p = 0.0041$; $52.9\% \pm 31.7\%$, $p = 0.0051$) and the LGA ($54.2\% \pm 44.2\%$, $p = 0.011$; $46.4\% \pm 36.7\%$, $p = 0.0061$) groups. No significant difference was observed between LGA and MISGA groups at 6- ($p = 0.93$) and 12-month ($p = 0.41$) follow-up.

3.3.4. Functional capacity improvement (ODI score)

ODI score improvement was significantly different between groups at 6- ($p = 0.028$) and 12-month ($p = 0.033$) follow-up. ODI score improvement was significantly higher for the MISAA group ($44.4 \pm 32.5\%$ at 6-month; $48.0 \pm 28.3\%$ at 12-month) than the MISGA group at 6-month ($26.8 \pm 34.0\%$, $p = 0.054$) and 12-month ($27.5 \pm 36.5\%$, $p = 0.019$) follow-ups, and higher than the LGA group at 12-month follow-up ($27.5 \pm 36.5\%$, $p = 0.024$). No significant differences of the ODI score improvement was observed between the MISAA group and the MISGA group at 6 months ($p = 0.054$), and the LGA group at 12 months ($p = 0.11$), or between the MISGA and LGA groups at 6 ($p = 0.72$) and 12 months ($p = 0.54$).

3.3.5. Health-related quality of life improvement (EQ-5D-3L)

EQ-5D-3L score improvement was significantly different between groups at 6- ($p = 0.039$) and 12-month ($p = 0.015$) follow-up. EQ-5D-3L score improvement was significantly higher for the MISAA group (0.31 ± 0.19 at 6-month; 0.26 ± 0.16 at 12-month) than the MISGA group at 6 (0.14 ± 0.25 , $p = 0.0028$) and 12 months (0.12 ± 0.27 , $p = 0.011$), and for the LGA group (0.25 ± 0.22) than the MISGA group (0.12 ± 0.27 , $p = 0.035$) at 12 months. No significant difference was found between the MISAA and LGA groups at 6 ($p = 0.074$) and 12 months ($p = 0.96$), or between MISGA and LGA at 6 months ($p = 0.73$).

3.3.6. Depression score decrease (MADRS)

MADRS score decrease was significantly different between groups at 6 ($p = 0.0003$) and 12 months ($p = 0.0005$). MADRS score decrease was significantly higher for the MISAA than the MISGA group at 6 (12.3 ± 12.0 vs 1.8 ± 7.2 , $p < 0.0001$) and 12 months (12.2 ± 9.4 vs 2.9 ± 9.9 , $p = 0.0002$). MADRS score decrease was significantly higher for the MISAA than the LGA group at 6 (12.3 ± 12.0 vs 3.5 ± 10.2 , $p = 0.009$) but not at 12 months (12.2 ± 9.4 vs 6.5 ± 10.5 , $p = 0.072$). The MADRS score of the MISGA group was not significantly different from the score of the LGA group at 6- ($p = 0.24$) and 12-month ($p = 0.27$).

3.3.6 Global Health Score improvement (GHS)

The first component in the PCA representing the global health score explained 57% of the common variance in the VAS, ODI, EQ5D, MADRS and pain surface. The GHS score improved significantly following SCS implantation, rising from 2.1 ± 2.2 to 6.1 ± 3.5 at 6 months ($p < 0.0001$) and to 6.6 ± 3.3 at 12 months ($p < 0.0001$).

GHS improvement was significantly different between groups at 6- ($p = 0.022$) and 12-month ($p = 0.018$) follow-up. GHS improvement was significantly higher for the MISAA group than for the MISGA group at 6 (5.8 ± 2.9 vs 3.5 ± 3.1 , $p = 0.006$) and 12 months (6.0 ± 2.5 vs 3.7 ± 3.3 , $p = 0.004$), and then the LGA group at 6-month (3.9 ± 3.4 , $p = 0.028$). No significant difference was found between the MISAA and LGA groups at 12 months ($p = 0.21$), or between MISGA and LGA at 6 months ($p = 0.52$) and 12 months ($p = 0.17$).

3.4. Safety analysis

All in all, 65 adverse events were observed among the implanted 108 patients. The most frequent adverse event was post-operative pain following lead and IPG implantations (24/108 implanted patients). The rates of post-operative device-related pain were significantly different among the three groups ($p = 0.00074$), with at least one adverse event occurring in 11/23 (47.8%) patients in the MISAA group, 12/52 (23.1%) in the MISGA group, and 1/28 (3.6%) in the LGA group.

The infection rates (11/108 patients) were significantly different between the groups ($p = 0.00033$), with 4/23 patients (17.4%) in the MISAA group, 0/52 (0%) patients in the MISGA group, and 7/28 patients (25.0%) in the LGA group. Two patients in the LGA group experienced epidural hematoma, which required an emergency reoperation.

4. Discussion

By investigating SCS performance, where implantation was achieved by combining MIS with AA (MISAA group), our study showed that intraoperative testing performed under awake anesthesia to optimize lead placement led to greater performance on short- (1 and 3 months) and long-term (6 and 12 months) outcomes, in comparison with SCS surgical implantation performed under general anesthesia, wherever the lead

was placed using MIS or open-surgical technique (MISGA and LGA groups). In addition, it appeared that greater SCS performance, assessed with an electronic interface, led to better clinical outcomes, since higher pain relief was obtained in the MISAA group for global and back pain at 6 months, and at 6 and 12 months for leg pain compared to MISGA and LGA groups.

4.1. Potential added-value of MIS to allow surgical SCS placement under awake conditions

In this study, all patients were implanted with a multicolumn SCS surgical lead by either MIS or laminectomy [33]. Originally designed for spinal decompressions and instrumentations, MIS has been shown to reduce blood loss, muscle injury and post-operative pain, leading to improved recovery periods and shortened hospitalization [36–41]. More specifically related to SCS implantation, the MAST approach appears to facilitate visualization of the spinal canal and to optimize lead placement by facilitating pure transligamentar median lead placement [28]. While less invasive, this approach is considered as technically demanding and may result in higher incidence of complications [36,38,41]. Beyond the specific context of surgical SCS and in congruence with Richard North's pivotal study comparing SCS vs spine reoperation in PSPS-T2 patients [6], our results emphasize the fact that adequate pain coverage is an important prerequisite to good patient outcome, when using tonic paraesthetic stimulation. In our innovative study, clinical outcomes were positively impacted by the MAST approach and awake anesthesia, which we were able to demonstrate with objective quantitative measurements using a dedicated software [16,29–32].

4.2. Combining MIS with TCIVA for surgical SCS implantation to facilitate patient intraoperative feedback

A previous prospective, multicenter study failed to report any differences of pain relief between patients implanted under awake or general anesthesia [42]. In contrast, our results showed that global, back and leg pain relief were greater for the MISAA group than for the MISGA and LGA groups at 6 months and remained greater for leg pain relief at 12 months. In addition, pain surface decrease was greater for the MISAA (69-76%) than the MISGA (44-54%) and LGA (56-58%) groups at 1 and 3 months, while the difference diminished at 6 and 12 months, ranging from 50 to 64%, whatever the group. Similar results were found in favor of the MISAA group for clinical outcomes including functional capacity, quality of life, depression and, more meaningfully, for our composite score. A multidimensional score, as recently recommended so as to ensure comprehensive assessment of complex pain [31,35,43], showed that patient health improvement was significantly greater in patients having undergone implantation under awake surgery and benefited from objective intraoperative assessment of SCS lead performance and selectivity.

4.3. The use of intraoperative pain mapping tool can help to optimize lead placement and programming, including waveform selection.

We have noted the potential impact of an intraoperative tactile interface, not only in terms of high-fidelity assessment, but also as a catalyzer of patient intraoperative cooperation, leading to more precise information regarding spatial targeting and lead programming, thereby influencing the decision to change SCS lead anatomical placement or leave it as it is, according to patient SCS anatomy [44].

Ultimately, during the initial programming session and after spatial optimization, it appears possible to initiate intraoperative testing to orient the choice of possible waveforms [17,18], by negative selection. In fact, exclusion of further paraesthetic stimulation, if immediate uncomfortable sensations are reported by the patient (especially in case of preexisting allodynia), can influence the final lead placement and tune down

the implanter's intolerance to imprecision. Subsequently, if conventional stimulation modalities need to be directly waived from on-table testing, infra-paraesthetic stimulation modalities or waveform combinations will be tried from the beginning of the trial period, in order to maximize opportunities.

In light of these results, awake surgery appears to achieve greater outcomes than general anesthesia, especially by means of the MAST approach [27,28], which facilitates intraoperative testing with objective pain mapping tools [16,29–32].

By comparing 11 patients implanted in awake surgery and 9 patients implanted in general anesthesia, both with laminectomy approach, Falowski et al. [42] showed greater paresthesia coverage in general anesthesia than awake surgery at 6 weeks (83.5% vs 46.6%). Considering our hypothesis that awake surgery is an interesting alternative means of improving electrode placement in cooperation with the patient, this result seems counterintuitive. First, the authors indicated that patient provided verbal feedback regarding paresthesia coverage, while we used a quantitative mapping tool to objectively delineate SCS performance. Second, they concluded that electromyographic testing under general anesthesia is faster and leads to greater lead placement accuracy. On this subject, while Falowski et al. [42] published interesting results in general anesthesia and neuro-monitoring of such patients, the average procedure time exceeded 125 minutes, whereas the average operating time in our study reached a maximum of 60 minutes. In addition to considering that infection rates increase according to length surgical procedure, in a vulnerable population where infection risk oscillates between 2.5-14% [3,4,45–47], we believe that given the ineluctable plastic reorganization of sensitive neural networks, one should not exclusively consider motor responses of neuro-electro-monitoring on implanted patients. We assume that intraoperative live feedback remains precious in integrating sensitive changes of the central nervous system such as collateral allodynia, which could, because of relative hypoesthesia due to the initial nervous lesion, limit the clinical outcome, notwithstanding good lead performance or asymmetric response to SCS. Lastly, a motor response by intraoperative EMG to select lead placement will not prevent jolting stimulation occurrence due to morphometrical spinal canal variability or dynamic impedance changes of the neural tissues at a certain level of stimulation; patient intraoperative feedback can.

However, one must remember that lead anatomical placement makes sense only if paresthesia/adequate coverage are needed and tonic conventional stimulation is used.

4.4. To what extent could hypnosis impact patient comfort during awake procedure?

It bears mentioning that awake surgery is clearly not considered as a gold standard for SCS implantation and could be perceived as increasing stress/anxiety and discomfort [42,48]. However, previous studies have demonstrated that epidural anesthesia can achieve satisfactory analgesic level with limited discomfort during SCS implantation with laminectomy [49,50]. In view of addressing potential discomfort issues, hypnosis has been introduced intraoperatively and demonstrated its efficacy [24,51,52]. In this study, we assume that patient comfort unambiguously improved thanks to hypnosis, according to reported patient satisfaction and perception of the technique [24]. In contrast, we must admit that for some patients, a negative impact and perception could occur due to "a priori" beliefs and anxiogenic representation of hypnosis techniques, during pre-operative patient education/preparation [53]. In fact, hypnosis can induce either a positive representation, markedly increasing therapeutic alliance, or else a negative perception, which will be unfavorable insofar as it aggravates patient anxiety [53] on entrance into the operating theatre for implantation. Our conviction is that intraoperative hypnosis could effectively optimize surgical implantation by adding comfort to a well-prepared patient and could decrease consumption of anesthetic drugs to make awake anesthesia more reversible [24]. It would also

reinforce collaboration between the patient and the implanter, the objectives being to obtain more reliable feedback and optimal intraoperative mapping. More recently, the use of intraoperative virtual reality to facilitate hypnotic induction during surgical procedures has been introduced [54–57] and we have incorporated this approach in our daily routine. However, intraoperative hypnosis + MISAA + virtual reality requires significant human resources and would not be easy to standardize.

In this study, we were not able to demonstrate that intraoperative hypnosis led to decreased IV pharmacological anesthetic agent consumption, since the TCIVA model, which depends on Body Mass Index (BMI) and individual sensitivity thresholds, is not transposable from one patient to another. TCIVA is also technically demanding for the anesthesiologist, since placing a TCIVA patient in prone position could lead to respiratory distress without it being possible to intubate in ventral decubitus. To avoid such complications, Vangeneugden [58] performed SCS implantation under spinal anesthesia, showing good results; however, as we aimed to transpose this approach to our practice, we observed a rostro-caudal gradient of diffusion of the anesthetic agents within the intrathecal and epidural space, which could modify patient perception intraoperatively and disturb paresthesia mapping [28]. Finally, this conclusion encouraged us to develop intraoperative hypnosis in combination with TCIVA so as to optimize surgical SCS implantation. Further studies including objective anesthetic drug consumption measurements will be required to more accurately assess its real benefits.

4.5. Study limitations & technical considerations

Despite encouraging results, this study has some limitations. First, the retrospective nature of this ancillary study limits the potential of extrapolation, by presenting a certain level of asymmetry between the three different groups of patients (MISAA=23, MISGA=52, LGA=33). For further research, a prospective comparative design would be more appropriate to randomize surgical technique allocations but at the price of potential ethical concerns and a lack of homogeneity between implanting centers.

Technical considerations. While SCS implantation under awake surgery showed encouraging results, this approach raises potential concerns and recommendations. Firstly, implanting an SCS multicolumn surgical lead while the patient is awake is technically demanding and should be reserved to experienced teams of anesthesiologists and spine surgeons.

Reported adverse events were more frequent in awake group (6/11: chest wall pain, numbness/weakness, loss of stimulation, unpleasant stimulation) than in the general anesthesia group (2/19: lead migration and persistent pain due to exacerbation of underlying back pain) [42]. Similarly, higher rates of adverse events with worse post-operative device-related pain were observed in the MISAA (11/23) than in the MISGA (12/52) and LGA (1/28) groups. This result seems quite coherent, considering that compared to MISGA and LGA patients, MISAA patients were less under post-operative influence of anesthetic agents. Questioning the patient retrospectively, after the surgical procedure, might have represented a subjective bias and should be carefully interpreted. In addition, infection rates were lower for patients having undergone the MAST approach (4/23 for the MISAA group and 0/52 in the MISGA group = 4/75 for MIS) in comparison with patients having undergone an open procedure (7/28 for the LGA group). It is safe to assume that the MAST approach could reduce infectious risk, as has been demonstrated for minimal invasive spinal surgery [27,28].

All in all, this study, despite its limitations, highlights the added value of combining intraoperative optimized anesthetic conditions and objective assessment in view of optimizing lead placement.

4.6. Does optimized lead positioning matter in 2022 ?

As theoretical evidence needs to be transposable to daily practice, this study raises further questions. Indeed, it is far from sure that our conclusion regarding SCS surgical implantation would fit with percutaneous lead implantation practice. Moreover, in an era of multiplied adjustments with temporal resolution of the signal, the privileging of spatial adjustments over temporal adjustments remains contestable.

In fact, different stimulation modalities such as burst, high frequency and high density, are currently used to optimize temporal targeting [13,15–17,59], and can now be combined according to patient preference [18].

A better option would probably consist in combining rather than opposing these two strategies [3]. Recent technological innovation offers new opportunities to shape and optimize the delivered electrical field by means of Multiple Independent Current Control (MICC™) technology [16,23]. Our vision is that when implanting SCS, neural spatial targeting, is of crucial importance, not only as it catalyzes spatial targeting by temporal resolution adjustments, but also in terms of electrical consumption, as it optimizes SCS lead implantation close to the target. One trend in our community consists in recommending specific vertebral levels of lead placement to capture specific dermatomes with a standardized approach, even under general anesthesia, which is opposite to of the concept described in this study. In a prospective cohort of 76 implanted patients, it was shown that optimized lead positioning can make a difference, when two consecutive patients enrolled in a prospective study did not show the same projection of the conus medullaris, which varied between T11 and L2 vertebral levels [44]. Conceptually, SCS goal is aimed at establishing a dialogue between electronics and neural structures, which would be organized according not to vertebral, but rather to myelomeric distribution. To make it clear, rather than recommending implantation of a lead at the T9-T10 vertebral level to capture a selected dermatome, we should recommend implantation at +5 myelomere above the conus medullaris, for which the anatomical projection is eminently variable [44]. This concept, if adopted, would define a “true anatomical placement”. Adding another level of granularity to anatomical somatotopic distribution, electrophysiological organization of the neural tissues, especially in case of neural plasticity secondary to a nerve injury, which defines neuropathic pain [60], could possibly map the neural fibers through live feedback [61], thereby confirming that technical placement has been optimized. With this in mind, the added value of intraoperative objective mapping testing appears to play a central role. Combined MIS+TCIVA offers this opportunity.

5. Conclusions

In this study, it appeared that chronic refractory pain PSPS-T2 patients implanted with SCS could substantially benefit from a combination of minimal invasive surgery, intraoperative quantitative pain and paresthesia mapping, and intraoperative hypnosis in view of optimizing SCS lead placement. However, this combined strategy is technically demanding and should be reserved to dedicated centers.

Ultimately, intraoperative clinical assessment of SCS leading to technical performance and selectivity presents a clear opportunity to compare different techniques, different SCS programs and to guide lead choice and lead placement, independently of from potential industry influence and based on objective and reliable comparative measurements of spatial targeting and temporal resolution optimization of the signal. This opportunity would require intraoperative patient feedback facilitated by the association of intraoperative techniques, objective assessment tools, hypnosis support and virtual reality developments. In an era of currently debated “No-Trial” [62–64], perspectives in favor of SCS direct implantation, designed to optimize technical aspects of SCS implantation, could help to delineate a crucial piece of this giant puzzle.

Author Contributions: Conceptualization, P.R.; methodology, P.R., A.O., M.R. and M.B.; software, K.N. and M.M.; formal analysis, A.O.; investigation, P.R., B.L., S.B.; writing—original draft preparation, P.R., A.O. and M.B.; writing—review and editing, P.R., A.O., M.M., L.G., M.R., P.P., B.L., S.B., K.N., M.M., T.T., R.D., C.W. and M.B.; supervision, P.R.; project administration, M.R.; funding acquisition, P.R. All authors have read and agreed to the published version of the manuscript.

Funding: The study received funding in 2012 from the French government National Health Service program “PSTIC 2011.” The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee CPP Ouest III and “ANSM” (number: 2011-A01695-36). The ClinicalTrials.gov Identifier is: NCT01628237.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Jeffrey Arsham for his proofreading of the manuscript and his suggestions regarding medical writing.

Conflicts of Interest: Philippe Rigoard reports grants and personal fees from Medtronic, grants and personal fees from Abbott, grants and personal fees from Boston Scientific, outside the submitted work. Maarten Moens reports speaker fees from Medtronic and Nevro, outside the submitted work. Philippe Page reports speaker fees from Medtronic, outside the submitted work. Amine Ounajim, Manuel Roulaud, Chantal Wood, Lisa Goudman, Bertille Lorgeoux, Sandrine Baron, Kevin Nivole, Mathilde Many, Romain David and Maxime Billot have nothing to disclose.

References

1. Duarte, R.V.; Nevitt, S.; McNicol, E.; Taylor, R.S.; Buchser, E.; North, R.B.; Eldabe, S. Systematic Review and Meta-Analysis of Placebo/Sham Controlled Randomised Trials of Spinal Cord Stimulation for Neuropathic Pain. *Pain* **2020**, *161*, 24–35, doi:10.1097/j.pain.0000000000001689.
2. Deer, T.R.; Grider, J.S.; Lamer, T.J.; Pope, J.E.; Falowski, S.; Hunter, C.W.; Provenzano, D.A.; Slavin, K.V.; Russo, M.; Carayannopoulos, A.; et al. A Systematic Literature Review of Spine Neurostimulation Therapies for the Treatment of Pain. *Pain Med* **2020**, *21*, 1421–1432, doi:10.1093/pm/pnz353.
3. Rigoard, P.; Billot, M.; Ingrand, P.; Durand-Zaleski, I.; Roulaud, M.; Peruzzi, P.; Dam Hieu, P.; Voirin, J.; Raoul, S.; Page, P.; et al. How Should We Use Multicolumn Spinal Cord Stimulation to Optimize Back Pain Spatial Neural Targeting? A Prospective, Multicenter, Randomized, Double-Blind, Controlled Trial (ESTIMET Study). *Neuromodulation* **2021**, *24*, 86–101, doi:10.1111/ner.13251.
4. Rigoard, P.; Basu, S.; Desai, M.; Taylor, R.; Annemans, L.; Tan, Y.; Johnson, M.J.; Van den Abeele, C.; North, R.; PROMISE Study Group. Multicolumn Spinal Cord Stimulation for Predominant Back Pain in Failed Back Surgery Syndrome Patients: A Multicenter Randomized Controlled Trial. *Pain* **2019**, *160*, 1410–1420, doi:10.1097/j.pain.0000000000001510.
5. Kumar, K.; Taylor, R.S.; Jacques, L.; Eldabe, S.; Meglio, M.; Molet, J.; Thomson, S.; O’Callaghan, J.; Eisenberg, E.; Milbouw, G.; et al. Spinal Cord Stimulation versus Conventional Medical Management for Neuropathic

- Pain: A Multicentre Randomised Controlled Trial in Patients with Failed Back Surgery Syndrome. *Pain* **2007**, 132, 179–188, doi:10.1016/j.pain.2007.07.028.
6. North, R.B.; Kidd, D.H.; Farrokhi, F.; Piantadosi, S.A. Spinal Cord Stimulation versus Repeated Lumbosacral Spine Surgery for Chronic Pain: A Randomized, Controlled Trial. *Neurosurgery* **2005**, 56, 98–106; discussion 106–107, doi:10.1227/01.neu.0000144839.65524.e0.
 7. Christelis, N.; Simpson, B.; Russo, M.; Stanton-Hicks, M.; Barolat, G.; Thomson, S.; Schug, S.; Baron, R.; Buchser, E.; Carr, D.B.; et al. Persistent Spinal Pain Syndrome: A Proposal for Failed Back Surgery Syndrome and ICD-11. *Pain Med* **2021**, doi:10.1093/pm/pnab015.
 8. Rigoard, P.; Delmotte, A.; D'Houtaud, S.; Misbert, L.; Diallo, B.; Roy-Moreau, A.; Durand, S.; Royoux, S.; Giot, J.-P.; Bataille, B. Back Pain: A Real Target for Spinal Cord Stimulation? *Neurosurgery* **2012**, 70, 574–584; discussion 584–585, doi:10.1227/NEU.0b013e318236a57c.
 9. Goudman, L.; Rigoard, P.; Billot, M.; Duarte, R.V.; Eldabe, S.; Moens, M. Patient Selection for Spinal Cord Stimulation in Treatment of Pain: Sequential Decision-Making Model - A Narrative Review. *JPR* **2022**, 15, 1163–1171, doi:10.2147/JPR.S250455.
 10. Taylor, R.S.; Taylor, R.J.; Van Buyten, J.-P.; Buchser, E.; North, R.; Bayliss, S. The Cost Effectiveness of Spinal Cord Stimulation in the Treatment of Pain: A Systematic Review of the Literature. *J Pain Symptom Manage* **2004**, 27, 370–378, doi:10.1016/j.jpainsymman.2003.09.009.
 11. Taylor, R.S.; Van Buyten, J.-P.; Buchser, E. Spinal Cord Stimulation for Chronic Back and Leg Pain and Failed Back Surgery Syndrome: A Systematic Review and Analysis of Prognostic Factors. *Spine (Phila Pa 1976)* **2005**, 30, 152–160, doi:10.1097/01.brs.0000149199.68381.fe.
 12. Taylor, R.S. Spinal Cord Stimulation in Complex Regional Pain Syndrome and Refractory Neuropathic Back and Leg Pain/Failed Back Surgery Syndrome: Results of a Systematic Review and Meta-Analysis. *J Pain Symptom Manage* **2006**, 31, S13–19, doi:10.1016/j.jpainsymman.2005.12.010.
 13. Deer, T.; Slavin, K.V.; Amirdelfan, K.; North, R.B.; Burton, A.W.; Yearwood, T.L.; Tavel, E.; Staats, P.; Falowski, S.; Pope, J.; et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. *Neuromodulation: Technology at the Neural Interface* **2018**, 21, 56–66, doi:10.1111/ner.12698.
 14. Deer, T.R.; Grigsby, E.; Weiner, R.L.; Wilcosky, B.; Kramer, J.M. A Prospective Study of Dorsal Root Ganglion Stimulation for the Relief of Chronic Pain. *Neuromodulation* **2013**, 16, 67–71; discussion 71–72, doi:10.1111/ner.12013.
 15. Goudman, L.; De Smedt, A.; Eldabe, S.; Rigoard, P.; Linderorth, B.; De Jaeger, M.; Moens, M.; Discover Consortium. High-Dose Spinal Cord Stimulation for Patients with Failed Back Surgery Syndrome: A Multicenter Effectiveness and Prediction Study. *Pain* **2021**, 162, 582–590, doi:10.1097/j.pain.0000000000002035.
 16. Rigoard, P.; Ounajim, A.; Goudman, L.; Banor, T.; Héroux, F.; Roulaud, M.; Babin, E.; Bouche, B.; Page, P.; Lorgeoux, B.; et al. The Challenge of Converting “Failed Spinal Cord Stimulation Syndrome” Back to Clinical Success, Using SCS Reprogramming as Salvage Therapy, through Neurostimulation Adapters Combined with 3D-Computerized Pain Mapping Assessment: A Real Life Retrospective Study. *J Clin Med* **2022**, 11, 272, doi:10.3390/jcm11010272.
 17. Billot, M.; Naiditch, N.; Brandet, C.; Lorgeoux, B.; Baron, S.; Ounajim, A.; Roulaud, M.; Roy-Moreau, A.; de Montgazon, G.; Charrier, E.; et al. Comparison of Conventional, Burst and High-Frequency Spinal Cord Stimulation on Pain Relief in Refractory Failed Back Surgery Syndrome Patients: Study Protocol for a Prospective Randomized Double-Blinded Cross-over Trial (MULTIWAVE Study). *Trials* **2020**, 21, 696, doi:10.1186/s13063-020-04587-6.

18. Rigoard, P.; Ounajim, A.; Goudman, L.; Roulaud, M.; Lorgeoux, B.; Baron, S.; Nivole, K.; Many, M.; Johnson, S.; David, R.; et al. Which Waveform for Which Patient? A Prospective Randomized Double-Blinded Cross-over Trial Comparing Pain Relief Using Tonic, Burst and High Frequency in PSPS-T2 Patients Implanted with Spinal Cord Stimulation (MULTIWAVE Study). *Submitted*.
19. Linderorth, B.; Foreman, R.D. Physiology of Spinal Cord Stimulation: Review and Update. *Neuromodulation* **1999**, *2*, 150–164, doi:10.1046/j.1525-1403.1999.00150.x.
20. Linderorth, B.; Foreman, R.D. Conventional and Novel Spinal Stimulation Algorithms: Hypothetical Mechanisms of Action and Comments on Outcomes. *Neuromodulation* **2017**, *20*, 525–533, doi:10.1111/ner.12624.
21. Goudman, L.; De Groote, S.; Linderorth, B.; De Smedt, A.; Eldabe, S.; Duarte, R.V.; Moens, M. Exploration of the Supraspinal Hypotheses about Spinal Cord Stimulation and Dorsal Root Ganglion Stimulation: A Systematic Review. *J Clin Med* **2021**, *10*, 2766, doi:10.3390/jcm10132766.
22. De Ridder, D.; Vanneste, S. Burst and Tonic Spinal Cord Stimulation: Different and Common Brain Mechanisms. *Neuromodulation* **2016**, *19*, 47–59, doi:10.1111/ner.12368.
23. Veizi, E.; Hayek, S.M.; North, J.; Brent Chafin, T.; Yearwood, T.L.; Raso, L.; Frey, R.; Cairns, K.; Berg, A.; Brendel, J.; et al. Spinal Cord Stimulation (SCS) with Anatomically Guided (3D) Neural Targeting Shows Superior Chronic Axial Low Back Pain Relief Compared to Traditional SCS-LUMINA Study. *Pain Med* **2017**, *18*, 1534–1548, doi:10.1093/pm/pnw286.
24. Wood, C.; Martiné, G.; Espagne-Dubreuilh, G.; Le Goff, K.; Moens, M.; Goudman, L.; Baron, S.; David, R.; Naïditch, N.; Billot, M.; et al. The Added Value of Intraoperative Hypnosis during Spinal Cord Stimulation Lead Implantation under Awake Anesthesia in Patients Presenting with Refractory Chronic Pain. *Medicina (Kaunas)* **2022**, *58*, 220, doi:10.3390/medicina58020220.
25. Wager, M.; Rigoard, P.; Bouyer, C.; Baudiffier, V.; Stal, V.; Bataille, B.; Gil, R.; Du Boisgueheneuc, F. Operating Environment for Awake Brain Surgery - Choice of Tests. *Neurochirurgie* **2017**, *63*, 150–157, doi:10.1016/j.neuchi.2016.10.002.
26. Wager, M.; Rigoard, P.; Bataille, B.; Guenot, C.; Supiot, A.; Blanc, J.-L.; Stal, V.; Pluchon, C.; Bouyer, C.; Gil, R.; et al. Designing an Operating Theatre for Awake Procedures: A Solution to Improve Multimodality Information Input. *Br J Neurosurg* **2015**, *29*, 829–835, doi:10.3109/02688697.2015.1054360.
27. Monlezun, O.; Voirin, J.; Roulaud, M.; Ingrand, P.; Veyrieras, C.; Brandet, C.; Bataille, B.; Guetarni, F.; Prévost, A.; Rigoard, P.; et al. “MAST” Prospective Study: Value of Minimal Access Spine Technologies Technique for Multicolumn Spinal Cord Stimulation Surgical Lead Implantation in the Context of a French Multicentre Randomized Controlled Trial (ESTIMET Study). *Neurochirurgie* **2015**, *61 Suppl 1*, S125-130, doi:10.1016/j.neuchi.2014.06.004.
28. Rigoard, P.; Luong, A.T.; Delmotte, A.; Raaholt, M.; Roulaud, M.; Monlezun, O.; Triphose, A.; Guetarni, F.; Brugière, B.; Misbert, L.; et al. Multicolumn Spinal Cord Stimulation Lead Implantation Using an Optic Transligamentar Minimally Invasive Technique. *Neurosurgery* **2013**, *73*, 550–553, doi:10.1227/NEU.0000000000000008.
29. Guetarni, F.; Rigoard, P. The “Neuro-Mapping Locator” Software. A Real-Time Intraoperative Objective Paraesthesia Mapping Tool to Evaluate Paraesthesia Coverage of the Painful Zone in Patients Undergoing Spinal Cord Stimulation Lead Implantation. *Neurochirurgie* **2015**, *61 Suppl 1*, S90-98, doi:10.1016/j.neuchi.2014.10.106.
30. Rigoard, P.; Nivole, K.; Blouin, P.; Monlezun, O.; Roulaud, M.; Lorgeoux, B.; Bataille, B.; Guetarni, F. A Novel, Objective, Quantitative Method of Evaluation of the Back Pain Component Using Comparative Computerized Multi-Parametric Tactile Mapping before/after Spinal Cord Stimulation and Database Analysis: The “Neuro-Pain’t” Software. *Neurochirurgie* **2015**, *61 Suppl 1*, S99–S108, doi:10.1016/j.neuchi.2014.09.003.

31. Rigoard, P.; Ounajim, A.; Goudman, L.; Louis, P.-Y.; Slaoui, Y.; Roulaud, M.; Naiditch, N.; Bouche, B.; Page, P.; Lorgeoux, B.; et al. A Novel Multi-Dimensional Clinical Response Index Dedicated to Improving Global Assessment of Pain in Patients with Persistent Spinal Pain Syndrome after Spinal Surgery, Based on a Real-Life Prospective Multicentric Study (PREDIBACK) and Machine Learning Techniques. *J Clin Med* **2021**, *10*, 4910, doi:10.3390/jcm10214910.
32. Rigoard, P.; Ounajim, A.; Goudman, L.; Bouche, B.; Roulaud, M.; Page, P.; Lorgeoux, B.; Baron, S.; Nivole, K.; Many, M.; et al. The Added Value of Subcutaneous Peripheral Nerve Field Stimulation Combined with SCS, as Salvage Therapy, for Refractory Low Back Pain Component in Persistent Spinal Pain Syndrome Implanted Patients: A Randomized Controlled Study (CUMPNS Study) Based on 3D-Mapping Composite Pain Assessment. *J Clin Med* **2021**, *10*, 5094, doi:10.3390/jcm10215094.
33. Roulaud, M.; Durand-Zaleski, I.; Ingrand, P.; Serrie, A.; Diallo, B.; Peruzzi, P.; Hieu, P.D.; Voirin, J.; Raoul, S.; Page, P.; et al. Multicolumn Spinal Cord Stimulation for Significant Low Back Pain in Failed Back Surgery Syndrome: Design of a National, Multicentre, Randomized, Controlled Health Economics Trial (ESTIMET Study). *Neurochirurgie* **2015**, *61 Suppl 1*, S109-116, doi:10.1016/j.neuchi.2014.10.105.
34. Rigoard, P.; Nivole, K.; Blouin, P.; Monlezun, O.; Roulaud, M.; Lorgeoux, B.; Bataille, B.; Guetarni, F. A Novel, Objective, Quantitative Method of Evaluation of the Back Pain Component Using Comparative Computerized Multi-Parametric Tactile Mapping before/after Spinal Cord Stimulation and Database Analysis: The “Neuro-Pain’t” Software. *Neurochirurgie* **2015**, *61 Suppl 1*, S99–S108, doi:10.1016/j.neuchi.2014.09.003.
35. Goudman, L.; Billot, M.; Duarte, R.V.; Eldabe, S.; Rigoard, P.; Moens, M. Gradation of Clinical Holistic Response as New Composite Outcome to Evaluate Success in Spinal Cord Stimulation Studies for Pain. *Neuromodulation* **2021**, S1094-7159(21)06395-9, doi:10.1016/j.neurom.2021.10.020.
36. Dhall, S.S.; Wang, M.Y.; Mummaneni, P.V. Clinical and Radiographic Comparison of Mini-Open Transforaminal Lumbar Interbody Fusion with Open Transforaminal Lumbar Interbody Fusion in 42 Patients with Long-Term Follow-Up. *J Neurosurg Spine* **2008**, *9*, 560–565, doi:10.3171/SPI.2008.9.08142.
37. Holly, L.T.; Schwender, J.D.; Rouben, D.P.; Foley, K.T. Minimally Invasive Transforaminal Lumbar Interbody Fusion: Indications, Technique, and Complications. *Neurosurg Focus* **2006**, *20*, E6, doi:10.3171/foc.2006.20.3.7.
38. Park, Y.; Ha, J.W. Comparison of One-Level Posterior Lumbar Interbody Fusion Performed with a Minimally Invasive Approach or a Traditional Open Approach. *Spine (Phila Pa 1976)* **2007**, *32*, 537–543, doi:10.1097/01.brs.0000256473.49791.f4.
39. Park, P.; Foley, K.T. Minimally Invasive Transforaminal Lumbar Interbody Fusion with Reduction of Spondylolisthesis: Technique and Outcomes after a Minimum of 2 Years’ Follow-Up. *Neurosurg Focus* **2008**, *25*, E16, doi:10.3171/FOC/2008/25/8/E16.
40. Rahman, M.; Summers, L.E.; Richter, B.; Mimran, R.I.; Jacob, R.P. Comparison of Techniques for Decompressive Lumbar Laminectomy: The Minimally Invasive versus the “Classic” Open Approach. *Minim Invasive Neurosurg* **2008**, *51*, 100–105, doi:10.1055/s-2007-1022542.
41. Schwender, J.D.; Holly, L.T.; Rouben, D.P.; Foley, K.T. Minimally Invasive Transforaminal Lumbar Interbody Fusion (TLIF): Technical Feasibility and Initial Results. *J Spinal Disord Tech* **2005**, *18 Suppl*, S1-6, doi:10.1097/01.bsd.0000132291.50455.d0.
42. Falowski, S.M.; Sharan, A.; McNerney, J.; Jacobs, D.; Venkatesan, L.; Agnesi, F. Nonawake vs Awake Placement of Spinal Cord Stimulators: A Prospective, Multicenter Study Comparing Safety and Efficacy. *Neurosurgery* **2019**, *84*, 198–205, doi:10.1093/neuros/nyy062.

43. Gewandter, J.S.; McDermott, M.P.; Evans, S.; Katz, N.P.; Markman, J.D.; Simon, L.S.; Turk, D.C.; Dworkin, R.H. Composite Outcomes for Pain Clinical Trials: Considerations for Design and Interpretation. *PAIN* **2021**, *162*, 1899–1905, doi:10.1097/j.pain.0000000000002188.
44. Delmotte, A.; Jacques, L.; Kumar, K.; Poon, K.; Monlezun, O.; Roulaud, M.; Prevost, A.; Munson, R.; Guetarni, F.; Bataille, B.; et al. The Franco-Canadian Multicolumn Spinal Cord Stimulation Prospective Study: A Subgroup Analysis Focusing on the Decisive Role of Lead Positioning. *Neurochirurgie* **2015**, *61 Suppl 1*, S83-89, doi:10.1016/j.neuchi.2014.06.005.
45. Bendersky, D.; Yampolsky, C. Is Spinal Cord Stimulation Safe? A Review of Its Complications. *World Neurosurg* **2014**, *82*, 1359–1368, doi:10.1016/j.wneu.2013.06.012.
46. Mekhail, N.; Levy, R.M.; Deer, T.R.; Kapural, L.; Li, S.; Amirdelfan, K.; Hunter, C.W.; Rosen, S.M.; Costandi, S.J.; Falowski, S.M.; et al. Long-Term Safety and Efficacy of Closed-Loop Spinal Cord Stimulation to Treat Chronic Back and Leg Pain (Evoke): A Double-Blind, Randomised, Controlled Trial. *Lancet Neurol* **2020**, *19*, 123–134, doi:10.1016/S1474-4422(19)30414-4.
47. North, R.; Desai, M.J.; Vangeneugden, J.; Raftopoulos, C.; Van Havenbergh, T.; Deruytter, M.; Remacle, J.-M.; Shipley, J.; Tan, Y.; Johnson, M.J.; et al. Postoperative Infections Associated With Prolonged Spinal Cord Stimulation Trial Duration (PROMISE RCT). *Neuromodulation* **2020**, *23*, 620–625, doi:10.1111/ner.13141.
48. Falowski, S.M.; Celii, A.; Sestokas, A.K.; Schwartz, D.M.; Matsumoto, C.; Sharan, A. Awake vs. Asleep Placement of Spinal Cord Stimulators: A Cohort Analysis of Complications Associated with Placement. *Neuromodulation* **2011**, *14*, 130–134; discussion 134-135, doi:10.1111/j.1525-1403.2010.00319.x.
49. García-Pérez, M.L.; Badenes, R.; García-March, G.; Bordes, V.; Belda, F.J. Epidural Anesthesia for Laminectomy Lead Placement in Spinal Cord Stimulation. *Anesth Analg* **2007**, *105*, 1458–1461, table of contents, doi:10.1213/01.ane.0000281153.02634.96.
50. Lind, G.; Meyerson, B.A.; Winter, J.; Linderöth, B. Implantation of Laminotomy Electrodes for Spinal Cord Stimulation in Spinal Anesthesia with Intraoperative Dorsal Column Activation. *Neurosurgery* **2003**, *53*, 1150–1153; discussion 1153-1154, doi:10.1227/01.neu.0000089107.67673.71.
51. Garcia, R.; Bouleti, C.; Li, A.; Frasca, D.; El Harrouchi, S.; Marechal, J.; Roumegou, P.; Corbi, P.; Christiaens, L.; Le Gal, F.; et al. Hypnosis Versus Placebo During Atrial Flutter Ablation: The PAINLESS Study: A Randomized Controlled Trial. *JACC Clin Electrophysiol* **2020**, *6*, 1551–1560, doi:10.1016/j.jacep.2020.05.028.
52. Noergaard, M.W.; Håkonsen, S.J.; Bjerrum, M.; Pedersen, P.U. The Effectiveness of Hypnotic Analgesia in the Management of Procedural Pain in Minimally Invasive Procedures: A Systematic Review and Meta-Analysis. *J Clin Nurs* **2019**, doi:10.1111/jocn.15025.
53. Billot, M.; Wood, C.; Moens, M.; Goudman, L.; Naiditch, N.; Roulaud, M.; Ounajim, A.; Rigoard, P. The Added Value of Intraoperative Hypnosis for Refractory Pain Patients Implanted with Spinal Cord Stimulation under Awake Conditions: A Retrospective Cohort Study. *Submitted*.
54. Mosso-Vázquez, J.L.; Gao, K.; Wiederhold, B.K.; Wiederhold, M.D. Virtual Reality for Pain Management in Cardiac Surgery. *Cyberpsychology, Behavior, and Social Networking* **2014**, *17*, 371–378, doi:10.1089/cyber.2014.0198.
55. Sweta, V.R.; Abhinav, R.P.; Ramesh, A. Role of Virtual Reality in Pain Perception of Patients Following the Administration of Local Anesthesia. *Ann Maxillofac Surg* **2019**, *9*, 110–113, doi:10.4103/ams.ams_263_18.
56. Hoffman, H.G.; Chambers, G.T.; Meyer, W.J.; Arceneaux, L.L.; Russell, W.J.; Seibel, E.J.; Richards, T.L.; Sharar, S.R.; Patterson, D.R. Virtual Reality as an Adjunctive Non-Pharmacologic Analgesic for Acute Burn Pain During Medical Procedures. *Annals of Behavioral Medicine* **2011**, *41*, 183–191, doi:10.1007/s12160-010-9248-7.
57. Hoxhallari, E.; Behr, I.J.; Bradshaw, J.S.; Morkos, M.S.; Haan, P.S.; Schaefer, M.C.; Clarkson, J.H.W. Virtual Reality Improves the Patient Experience during Wide-Awake Local Anesthesia No Tourniquet Hand Surgery:

- A Single-Blind, Randomized, Prospective Study. *Plastic and Reconstructive Surgery* **2019**, *144*, 408–414, doi:10.1097/PRS.0000000000005831.
58. Vangeneugden, J. Implantation of Surgical Electrodes for Spinal Cord Stimulation: Classical Midline Laminotomy Technique versus Minimal Invasive Unilateral Technique Combined with Spinal Anaesthesia. *Acta Neurochir Suppl* **2007**, *97*, 111–114, doi:10.1007/978-3-211-33079-1_15.
 59. Rigoard, P.; Roulaud, M.; Goudman, L.; Adjali, N.; Ounajim, A.; Voirin, J.; Perruchoud, C.; Bouche, B.; Page, P.; Guillevin, R.; et al. Comparison of Spinal Cord Stimulation vs. Dorsal Root Ganglion Stimulation vs. Association of Both in Patients with Refractory Chronic Back and/or Lower Limb Neuropathic Pain: An International, Prospective, Randomized, Double-Blinded, Crossover Trial (BOOST-DRG Study). *Medicina (Kaunas)* **2021**, *58*, 7, doi:10.3390/medicina58010007.
 60. Bennett, G.J.; Xie, Y.-K. A Peripheral Mononeuropathy in Rat That Produces Disorders of Pain Sensation like Those Seen in Man. *Pain* **1988**, *33*, 87–107, doi:10.1016/0304-3959(88)90209-6.
 61. Rigoard, P.; Moens, M.; Goudman, L.; Le Tutor, T.; Dany, J.; Et Talby, M.; Hervochon, R.; Roulaud, M.; Ounajim, A.; Frasca, D.; et al. The “Neuro-Fiber-Mapping”: An Original Concept of Spinal Cord Neural Activation Spatial Targeting Using Live Electrostimulation Mapping to (Re)Explore the Conus Medullaris Anatomy. *Submitted*.
 62. Eldabe, S.; Duarte, R.V.; Gulve, A.; Thomson, S.; Baranidharan, G.; Houten, R.; Jowett, S.; Sandhu, H.; Chadwick, R.; Brookes, M.; et al. Does a Screening Trial for Spinal Cord Stimulation in Patients with Chronic Pain of Neuropathic Origin Have Clinical Utility and Cost-Effectiveness (TRIAL-STIM)? A Randomised Controlled Trial. *Pain* **2020**, *161*, 2820–2829, doi:10.1097/j.pain.0000000000001977.
 63. Thomson, S.; Huygen, F.; Prangnell, S.; De Andrés, J.; Baranidharan, G.; Belaïd, H.; Berry, N.; Billet, B.; Cooil, J.; De Carolis, G.; et al. Appropriate Referral and Selection of Patients with Chronic Pain for Spinal Cord Stimulation: European Consensus Recommendations and e-Health Tool. *Eur J Pain* **2020**, *24*, 1169–1181, doi:10.1002/ejp.1562.
 64. Ounajim, A.; Billot, M.; Goudman, L.; Louis, P.-Y.; Slaoui, Y.; Roulaud, M.; Bouche, B.; Page, P.; Lorgeoux, B.; Baron, S.; et al. Machine Learning Algorithms Provide Greater Prediction of Response to SCS Than Lead Screening Trial: A Predictive AI-Based Multicenter Study. *J Clin Med* **2021**, *10*, 4764, doi:10.3390/jcm10204764.